A Study of EOC237 in Patients With Advanced Solid Tumor

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

Key facts

Study ID

NCT05895825

Run by

Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd

People needed

48

Starts

2023-07-26

Expected to finish

2026-09-30

Last updated by the study team

2023-11-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.
• Expected survival≥ 3 months.
• ECOG performance status 0-1.
• Good organ and marrow function.

You may not qualify if…

• Patients with a history of severe drug allergic reaction.
• Pregnant or lactating female subjects.
• Uncontrolled, significant intercurrent or recent illness.
• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG)
• Concomitant use of certain medications

Where it is running

• National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.